ASCT Viewpoint
Jun. 11, 2014

Makers of HPV vaccine working on stronger version
A stronger vaccine is in the works to protect young people from the human papillomavirus. The makers of Gardasil, which was developed at the University of Rochester, say they are working on an experimental vaccine that can protect against nine different HPV strains.More

Ask ASCT has been updated
ASCT members have access to a wealth of knowledge and resources. Check the "Ask ASCT" directory of 16 topics and 19 contact people. Topics include CAP Inspection, Competency Assessment, Lab Design, Test Validation and Personnel Management. You can email your questions directly from the ASCT website. Visit the Member's Only section to access "Ask ASCT."More

Shop for ASCT products online

Searching for the perfect cytology graduation gift? Look no further! ASCT offers microscope lapel pins, HPV plushies, mini-notebooks, cytology playing cards, ASCT tote bags, polo shirts, baseball caps and cytology notecards. Check them out here. Happy Shopping!More

Immune therapy shows promise against cervical cancer
Two years ago, Arrica Wallace was riddled with tumors from widely spread cervical cancer that the strongest chemotherapy and radiation could not beat back. Today, the Kansas mother shows no signs of the disease, and it was her own immune system that made it go away. The experimental approach that helped her is one of the newest frontiers in the rapidly advancing field of cancer immunotherapy, which boosts the body's natural ways of attacking tumors.More

HPV home testing kits coming soon
Design & Trend
The human papillomavirus is the most common sexually transmitted infection in the United States. While there are many different types, some pose a greater risk to those infected than others. Some strains of HPV are directly linked to cervical cancer risk, while others appear to have no overall effect on a woman's health. A 2011 study put out by The Centers for Disease Control and Prevention found that 43 percent of girls and women between the ages of 14-59 are infected with HPV.More

Moral concerns hamper HPV vaccine
MedPage Today
Moral concerns about the human papillomavirus vaccine were the greatest barrier to vaccination among college freshmen, according to researchers here. When 18- and 19-year-old students at one university were surveyed about perceived barriers to receiving the quadrivalent HPV recombinant vaccine (Gardasil), 91.2 percent cited a composite of morality-related issues, said Jamie Phillipich, M.S., and Margaret Webb, M.S., from Grand Valley State University in Grand Rapids, Mich.More

Startup turns smartphone into cervical cancer detector
The Wall Street Journal
Doctors already use iPhone add-ons to take electrocardiograms just about anywhere. Apps can help radiologists read images and allow patients to monitor moles to determine if they're a cancer worry. MobileOCT, an Israeli tech company, has unveiled the latest advance in mobile medicine. It's a smartphone-fitted colposcope aimed at developing countries like Kenya, Rwanda and Haiti, desperate for cheap ways of detecting cervical cancer, a major killer in these places.More

Biomedical scientists explore mechanisms of novel treatments for HCV
As new treatments for hepatitis C virus are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus. An online publication in Hepatology is the first to report real-time tracking of viral decay in the liver and blood in 15 patients with HCV.More

Reduced-dose radiation safe for certain patients with low-risk HPV-positive oropharyngeal cancer
Oncology Nurse Advisor
Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus-positive head and neck cancer appears to be safe and might improve patients' quality of life, according to research presented at the 2014 American Society of Clinical Oncology Annual Meeting.More